DFTX - Mind Medicine (MindMed) Inc.

17.88
-1.060   -5.928%

Share volume: 1,743,354
Last Updated: 03-27-2026
Pharmaceutical Products/Medicinal Chemicals: -0.12%

PREVIOUS CLOSE
CHG
CHG%
$18.94
-1.06
-0.06%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
56%
Profitability 50%
Dept financing 37%
Liquidity 45%
Performance 70%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0.51%
1 Month
4.07%
3 Months
32.84%
6 Months
48.50%
1 Year
205.64%
2 Year
87.82%
Key data
Stock price
$17.88
P/E Ratio 
0.00
DAY RANGE
$17.66 - $18.84
EPS 
-$2.06
52 WEEK RANGE
$4.70 - $19.67
52 WEEK CHANGE
$205.64
MARKET CAP 
1.319 B
YIELD 
N/A
SHARES OUTSTANDING 
99.698 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
1.95
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,736,372
AVERAGE 30 VOLUME 
$1,788,029
Company detail
CEO: Robert Barrow
Region: US
Website: mindmed.co
Employees: 40
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Medicinal Chemicals
Sector: Manufacturing

Mind Medicine (MindMed) Inc. develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder.

Recent news